Insider Selling: Natera, Inc. (NASDAQ:NTRA) Director Sells $350,668.36 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 2,212 shares of the firm’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $158.53, for a total value of $350,668.36. Following the completion of the transaction, the director now owns 19,386 shares of the company’s stock, valued at approximately $3,073,262.58. This represents a 10.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Natera Price Performance

Shares of Natera stock opened at $146.06 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.01. The business’s 50 day simple moving average is $127.38 and its two-hundred day simple moving average is $115.76. The stock has a market capitalization of $19.28 billion, a P/E ratio of -82.99 and a beta of 1.53. Natera, Inc. has a one year low of $52.01 and a one year high of $167.79.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s quarterly revenue was up 63.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.95) EPS. Analysts forecast that Natera, Inc. will post -1.7 EPS for the current year.

Hedge Funds Weigh In On Natera

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC increased its stake in Natera by 1,073.1% in the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after purchasing an additional 60,127 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Natera by 15.1% during the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after buying an additional 9,781 shares during the period. Chartwell Investment Partners LLC increased its stake in shares of Natera by 37.9% during the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after buying an additional 11,362 shares during the period. Natixis purchased a new position in shares of Natera during the first quarter valued at approximately $758,000. Finally, Baader Bank Aktiengesellschaft purchased a new position in shares of Natera during the second quarter valued at approximately $478,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NTRA has been the subject of several analyst reports. BTIG Research raised their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. UBS Group dropped their price target on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Canaccord Genuity Group lifted their price target on Natera from $150.00 to $165.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. TD Cowen lifted their price target on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, Craig Hallum lifted their price target on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average target price of $137.65.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.